1530.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 11:08):

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...

Stats
Šios dienos apimtis	10.09M
Vidutinė apimtis	17.65M
Rinkos kapitalizacija	14.58B
EPS	HKD0 ( 2024-03-20 )
Kita pelno data	( HKD0 ) 2024-06-19
Last Dividend	HKD0.100 ( 2023-06-27 )
Next Dividend	HKD0 ( N/A )
P/E	9.07
ATR14	HKD0.0120 (0.20%)

Tūris Koreliacija

Ilgas: 0.05 (neutral)

Trumpas: -0.75 (moderate negative)

Signal:(44.48) Neutral

3SBio Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

3SBio Inc Koreliacija - Valiuta/Žaliavos

0.60
( weak )

0.30
( neutral )

0.00
( neutral )

0.49
( neutral )

0.00
( neutral )

0.23
( neutral )

3SBio Inc Finansinės ataskaitos

Annual	2023
Pajamos:	HKD7.82B
Bruto pelnas:	HKD6.64B (84.98 %)
EPS:	HKD0.620

FY	2023
Pajamos:	HKD7.82B
Bruto pelnas:	HKD6.64B (84.98 %)
EPS:	HKD0.620

FY	2022
Pajamos:	HKD6.86B
Bruto pelnas:	HKD5.67B (82.69 %)
EPS:	HKD0.780

FY	2021
Pajamos:	HKD6.38B
Bruto pelnas:	HKD5.28B (82.67 %)
EPS:	HKD0.650

Financial Reports:

No articles found.

3SBio Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.100 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

3SBio Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.29 - Stable (5.83%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0685	2018-06-29
Last Dividend	HKD0.100	2023-06-27
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.369	--
Avg. Dividend % Per Year	0.00%	--
Score	2.64	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.29
Div. Directional Score	8.05	--

Next Divdend (Est)
(2026-02-03)

HKD0 Estimate 2.74 %

Dividend Stability

0.22 Very Poor

Dividend Score

2.64

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8037.HK	No Dividend Player	2023-05-19	Sporadic	0.00%
1997.HK	Ex Dividend Junior	2023-08-25	Semi-Annually	0.00%
1070.HK	Ex Dividend Junior	2023-07-18	Annually	0.00%
0144.HK	Ex Dividend Knight	2023-09-26	Semi-Annually	0.00%
3658.HK	Ex Dividend Knight	2023-09-28	Annually	0.00%
1618.HK	Ex Dividend Junior	2023-07-27	Annually	0.00%
0677.HK	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
9989.HK	Ex Dividend Junior	2023-05-24	Annually	0.00%
2196.HK	Ex Dividend Junior	2023-07-31	Annually	0.00%
1203.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.198	1.500	6.04	9.05	[0 - 0.5]
returnOnAssetsTTM	0.0656	1.200	7.81	9.38	[0 - 0.3]
returnOnEquityTTM	0.112	1.500	9.86	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.47	0.800	2.67	2.14	[1 - 3]
quickRatioTTM	1.901	0.800	3.52	2.82	[0.8 - 2.5]
cashRatioTTM	0.722	1.500	7.10	10.00	[0.2 - 2]
debtRatioTTM	0.204	-1.500	6.59	-9.89	[0 - 0.6]
interestCoverageTTM	23.36	1.000	2.46	2.46	[3 - 30]
operatingCashFlowPerShareTTM	0.485	2.00	9.84	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.353	2.00	9.82	10.00	[0 - 20]
debtEquityRatioTTM	0.344	-1.500	8.62	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.850	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.300	1.000	5.99	5.99	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.245	1.000	9.75	9.75	[0.2 - 2]
assetTurnoverTTM	0.331	0.800	-1.128	-0.902	[0.5 - 2]
Total Score				10.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.87	1.000	9.21	0	[1 - 100]
returnOnEquityTTM	0.112	2.50	9.91	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.353	2.00	9.88	10.00	[0 - 30]
dividendYielPercentageTTM	1.778	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.485	2.00	9.84	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.152	1.000	8.71	0	[0.1 - 0.5]
Total Score				5.29

3SBio Inc

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.